Philips Enhances Neurological Diagnosis with the Launch of IntelliSpace Portal 9.0

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) has announced the introduction of IntelliSpace Portal 9.0, the latest edition of its comprehensive, advanced visual analysis and quantification platform. Featuring a suite of multi-modality functions and expanded neurological tools, IntelliSpace Portal 9.0 helps radiologists detect, diagnose and follow-up on treatment of diseases, while using new machine learning capabilities to support the physician. The solution addresses radiologists' needs for tools to better support the growing group of patients with brain injuries and neurological disorders such as dementia, strokes, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

In addition to enhancements in areas such as CT Brain Perfusion and MR T2 Perfusion IntelliSpace Portal 9.0 will offer Longitudinal Brain Imaging (LoBI) , an application for neuro reading to support the evaluation of neurological disorders over time so clinicians can monitor disease progression. Another feature is the inclusion of the NeuroQuant® measurement application (CorTech Labs, Inc.) which enables clinicians to quantify brain volume loss.

"As the rates of dementia and neurodegeneration rise, neuroradiologists need advanced tools to help referring physicians treat these challenging cases," said Professor Dr. Leo Wolansky, Acting Chief of Neuroradiology at University Hospitals Cleveland Medical Center in the United States. "IntelliSpace Portal 9.0 offers a comprehensive set of robust tools so neuroradiologists can quantify disease expediently."

With more than 70 applications and enhancements of many of the core applications, IntelliSpace Portal 9.0 is a single platform for visual analysis and quantification that spans clinical domains within radiology, including neurology, oncology, and cardiology. The platform offers improved advanced 3D rendering and refined STL export that enable clinicians to print 3D models with high-levels of detail and resolution, to help understand the anatomy. IntelliSpace Portal 9.0 also includes enhancements to a host of core applications from MR Cardiac Analysis to CT TAVI planning, and System enhancements.

"Radiology has a unique ability to influence and improve outcomes, and intelligent tools enable us to empower radiologists with the right information," said Yair Briman, Senior Vice President and General Manager of Healthcare IT for Philips. "With advances in machine learning, IntelliSpace Portal 9.0 will now be able to continually learn the usage patterns of users to enhance the important daily functions of a radiologist such as pre-preprocessing of images, encouraging faster and more streamlined diagnosis."

IntelliSpace Portal 9.0 offers multimodality clinical applications that can be accessed from any point of the hospital network. The solution can also integrate with typical PACS and hospital information systems to allow for information to be shared broadly, helping drive collaboration across the network. With the enterprise scalability of IntelliSpace Portal 9.0, neurologists can access the power of advanced analysis virtually anywhere across their organization while maintaining consistent applications and user preferences. Some additional highlights of Version 9.0 of the Portal include:

  • MR Cardiac Enhancements - Facilitates easy visual scoring in various examination contexts. The package enables comprehensive functional volumetric analysis. Enhancements to the package include Whole Heart STL export for 3D printing, and enhanced workflow and batch tools.
  • CT Spectral Applications - Philips IntelliSpace Portal Spectral Diagnostic suite of clinical applications has been optimized for the viewing and analysis of spectral data sets from the IQon Spectral CT scanner. You can access the application you need when and where you need, virtually anywhere in your enterprise. The tools help you gain a comprehensive overview of each patient, quantify quickly, and diagnose with confidence.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 70,000 employees with sales and services in more than 100 countries.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...